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effective. Univariate sensitivity analyses showed that changes in the costs of atorvas-
tatin, and in treatment duration have the biggest impact on the results. Subsequent 
probabilistic analyses will be used to further explore uncertainties around the 
estimates.
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OBJECTIVES: To estimate the cost effectiveness of rivaroxaban against enoxaparin 
for the prophylaxis of venous thromboembolism (VTE) in patients after total hip 
replacement (THR) in Slovakia from payer perspective. METHODS: A cost-utility 
model based on results of large randomized controlled trial (RECORD 1) was devel-
oped. In RECORD1, patients received 35 days prophylaxis with rivaroxaban or 
enoxaparin. Rivaroxaban reduced total VTE (composite: any DVT, non-fatal PE, 
all-cause mortality) by 70% versus enoxaparin after 35 days prophylaxis. The model 
was divided into three parts: prophylaxis, post-prophylaxis, and long-term complica-
tions. The ﬁrst two parts represents acute phase and were modeled as a decision tree. 
Third part represents the long-term complications and was developed as a Markov 
model. The ﬁrst part of the model is populated by RECORD 1 trial, while published 
epidemiological and clinical data estimating the risk of further VTE events and post-
thrombotic syndrome beyond the trial period were used in second and third part of 
the model. Local cost data was based on published price lists, clinical guidelines, 
product labels and expert opinion. VTE related utilities were used from literature. 
Effectiveness was measured in quality-adjusted life years (QALY). Time horizon was 
set at 5 years and payers perspective was used. Discount rate was 7% per year for 
costs and effects according to Ministry of Health (MoH) guidelines for health eco-
nomic evaluation valid in 2008. One-way and probabilistic sensitivity analyses were 
performed. RESULTS: Rivaroxaban was cost-effective versus enoxaparin, with an 
incremental cost per QALY of 39672.10. This is signiﬁcantly below ofﬁcially pub-
lished 326,500 /QALY threshold for willingness to pay in Slovakia. Over 1,000 
samples of probabilistic sensitivity analysis, 633 simulations were below a threshold 
of 326,500. CONCLUSIONS: Rivaroxaban is a cost-effective alternative to enoxapa-
rin for the prevention of VTE following THR in Slovakian setting.
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OBJECTIVES: Aspirin prevents myocardial infarction (MI), but increases gastrointes-
tinal bleeding (GIB) and dyspepsia. Proton pump inhibitors (PPIs) reduce GIB risk and 
dyspepsia, but economic implications of use with aspirin has not been studied. We 
examine cost-utility of low-dose aspirin + PPI (omeprazole) 20 mg daily; low-dose 
aspirin alone; or no therapy for primary cardiovascular (CVD) prevention. METHODS: 
We develop a Markov model and performed a lifetime analysis of middle-aged and 
older men without history of CVD at levels of 10-year risk for coronary heart disease 
(CHD) events from 2.5% to 25%, using a third-party payer perspective. Baseline risks 
of MI, stroke, and CHD death were estimated from Framingham equations. Baseline 
risks of GIB and dyspepsia were estimated from cohort studies. Non-cardiovascular 
mortality obtained from US life tables. From systematic reviews, aspirin reduced CHD 
events by 30%, increased total stroke risk by 6%, increase risk of dyspepsia by 80%, 
and increase risk of GIB 2-fold for patients without history of GIB and 10-fold for 
patients with history of GIB. Addition of PPI reduced GIB risk by 90% and dyspepsia 
by 50%. RESULTS: For the base case of 45-year-old men with 10-year risk for CHD 
events of 10%, aspirin alone was more effective and less costly than no treatment. 
Aspirin + PPI (compared with aspirin alone) had cost/QALY of $473,673 when 
dyspepsia is not modeled and $51,059 when the effects of treating dyspepsia are 
included. The incremental cost/QALY of adding PPI was found to improve as CHD 
or GIB risk increases. CONCLUSIONS: Aspirin for CHD prevention is cost-saving in 
men over 45 with a 10-year CHD risk of 10% or greater. When the beneﬁts from 
treating dyspepsia are not included, adding PPI is not cost-effective as a routine means 
of preventing GI bleeding. The cost-effectiveness of adding PPI to aspirin is dependent 
on PPI cost and protective effect against GI adverse events.
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OBJECTIVES: Regadenoson, a newer adenosine derivative, has improved pharmaco-
logic properties that may improve safety proﬁle and administrative requirements 
compared to adenosine and dipyridamole. This study assessed the economic beneﬁts 
of utilizing regadenoson in myocardial perfusion imaging (MPI). METHODS: Data 
on the overall laboratory and individual staff time spent on MPI procedures and 
managing adverse events was collected from 141 cardiovascular laboratories. Direct 
laboratory MPI cost was estimated by applying hourly labor and fringe beneﬁt rates 
to the amount of time each staff was involved in the test. In addition, the cost of the 
agent and its administration also was applied. Regression analysis was used to examine 
the association between laboratory characteristics and the weekly number of tests. 
The estimated adjusted mean values were used to test the sensitivity of results to this 
parameter. RESULTS: Assuming a set number of 20 tests/week with adenosine and 
dipyridamole, shorter overall test time with regadenoson (mean [± SD] of 156 ± 46 
minutes vs. 182 ± 63 minutes with adenosine and 191 ± 61 minutes with dipyridamole) 
and utilization less of laboratory resources resulted in an additional 177 and 244 tests/
year with regadenoson vs. other agents, respectively. The annual savings with regad-
enoson were $17,377 vs. adenosine and $36,677 vs. dipyridamole in laboratory 
personnel cost and $91,165 vs. adenosine in total cost. Regadenoson resulted in 
$112,134 higher annual total cost compared to dipyridamole due to higher drug-
related costs. CONCLUSIONS: The ﬁndings from this analysis suggest that regadeno-
son will reduce the direct cost of MPI by decreasing the procedure and monitoring 
time and increasing patient throughput. These ﬁndings will be of interest to laboratory 
administrators and payers.
PCV89
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OBJECTIVES: Previous studies suggest prasugrel may be cost effective when com-
pared to clopidogrel for treating acute coronary syndrome patients (ACS). Recent 
research has shown that the reduced function allele CYP2C19*2 (*2 allele) is associ-
ated with an increased risk of adverse events for ACS patients taking clopidogrel and 
a decreased risk for patients taking prasugrel. The purpose of this paper is to test 
whether using clopidogrel for all patients is cost effective compared to prasugrel for 
*2 allele patients in combination with clopidogrel for non *2 patients and to prasugrel 
only for New Zealand. METHODS: Effectiveness of clopidogrel and prasugrel from 
published TRITON-TIMI 38 clinical trials was combined with rates of *2 occurrence 
in Maori, Paciﬁc Islanders, Asian and NZ European and national hospital records on 
rates and costs of hospitalisations 15 months post ACS for stroke, MI, bleeding, stent 
thrombosis and cardiovascular death. Decision tree modelling and Monte Carlo simu-
lations examined the robustness of the results. RESULTS: Rates of the *2 allele differ 
signiﬁcantly between NZ European (15%), Maori (24%), Asian (29%) and Paciﬁc 
People (45%). Analysis of hospital records suggest that rates of MI, stroke, bleeding, 
stent thrombosis and cardiovascular death were much higher in the general New 
Zealand population than in the clinical trial population. The cost effectiveness analysis 
suggests that use of a genetic test to guide combined use of clopidogrel and prasugrel 
was cost effective for most age and ethnic groups, but particularly for Maori males 
(NZ$3184/QALY), Maori females (NZ$3687/QALY), Paciﬁc men (NZ$4617/QALY) 
and Paciﬁc women (NZ$7605/QALY). Prasugrel is more costly and less effective than 
clopidogrel. CONCLUSIONS: The results here suggest that the use of a genetic test 
to guide treatment decisions for ACS patients is cost effective, especially for Maori 
and Paciﬁc peoples, and that prasugrel alone is not cost effective in New Zealand.
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COST-EFFECTIVENESS OF ATORVASTATIN IN ACUTE CORONARY 
SYNDROME PATIENTS IN SWEDEN
Thurston S1, Webb C2, Borgman B3, Van Hout B1
1Pharmerit Ltd, York, UK, 2Pﬁzer Limited, Tadworth, Surrey, UK, 3Pﬁzer Sweden, 
Sollentuna, Sweden
OBJECTIVES: To estimate the clinical and economic outcome of treatment with 
atorvastatin 80 mg versus simvastatin 40 mg and pravastatin 40 mg in Swedish 
patients with acute coronary syndrome (ACS). Simvastatin 40 mg was selected for the 
analysis based on current clinical treatment practices. METHODS: Efﬁcacy is esti-
mated based on a Bayesian meta-analysis linking decrease in LDL cholesterol levels 
to decreases in secondary cardiovascular (CV) events (MIs, strokes, CV deaths) 
drawing data from statin trials in ACS (MIRACL, PROVE-IT, AtoZ) and using priors 
from published statin meta analyses (CTT, Law). A Markov model combines estimates 
of the occurrence of later events; Swedish cost data; and quality of life. Baseline risks 
are taken from the ACS CURE study. Analyses are conducted using a baseline event 
risk during the ﬁrst 6 months of 12.1% and of 3.89% during later months. The time 
horizon of the analyses is lifetime (50 years). RESULTS: Treatment with atorvastatin 
during the acute phase (three months after event) instead of the comparator yields a 
cost per QALY of 68,784 Swedish kronor (SEK) compared with simvastatin, and of 
45,342 SEK compared with pravastatin. Taking mandatory price cuts of 70% at LOE 
into account, the cost per QALY for lifetime treatment with atorvastatin is 46,056 
SEK compared with simvastatin, and 28,113 SEK compared with pravastatin. ICERs 
improve when risk with age is reduced, lower discount rates are used, and when 
atorvastatin cost is decreased. CONCLUSIONS: Preliminary ﬁndings show that, based 
on currently accepted Swedish cost effectiveness thresholds, using atorvastatin 80 mg 
to treat high risk Swedish ACS patients is a cost-effective intervention, either versus 
simvastatin or pravastatin. Univariate sensitivity analyses showed that changes in the 
costs of atorvastatin, and in treatment duration have the biggest impact on the results. 
Abstracts A167
Subsequent probabilistic analyses will be used to further explore uncertainties around 
the estimates.
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OBJECTIVES: Individuals with type 2 diabetes mellitus (T2DM) utilize more health 
care resources than those without diabetes, yet a portion of the increased use may be 
due to comorbid conditions. This study compared health care resource utilization 
among adults with T2DM plus hypertension (HTN) and obesity with those with 
T2DM only. METHODS: Respondents to the Study to Help Improve Early evaluation 
and management of risk factors Leading to Diabetes (SHIELD), a large US survey, 
self-reported their height, weight, comorbid conditions, number of hospitalizations, 
emergency department (ED) visits, and physician visits in the past 12 months. Respon-
dents reporting T2DM and HTN and obesity (body mass index [BMI] ≥30 kg/m2) 
were identiﬁed and compared with a T2DM-only group. RESULTS: T2DM respon-
dents with, comorbid HTN, and obesity (n = 1186), were younger, more likely to be 
men, and had lower income but were similar to T2DM-only respondents (n = 293) in 
race, education, smoking, and cardiovascular disease history. Respondents with 
T2DM, HTN, and obesity had signiﬁcantly more physician visits (mean of 8 vs. 6, p 
= 0.001), especially 10 or more visits (21% vs. 15%), than respondents with T2DM 
only (p = 0.03). No signiﬁcant differences (p > 0.05) were reported for percentage 
hospitalized (21% vs. 20%) and number of days hospitalized (mean of 7 vs. 11 days) 
over the past 12 months. Respondents with comorbid HTN and obesity reported 
signiﬁcantly more ED visits (9% with 2–13 visits) compared with T2DM-only group 
(5% with 2–5 visits, p = 0.02). CONCLUSIONS: Respondents with comorbid condi-
tions of T2DM, HTN, and obesity have greater health care resource utilization in 
physician ofﬁce visits and ED visits than those with T2DM only.
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OBJECTIVES: Resource utilisation data were collected in all three Dabigatran etexi-
late (DBG) Phase III primary VTE prevention following orthopaedic surgery studies. 
This study aimed to, within trial, summarise resource use by treatment group and 
compare resource use separately for each dose of orally-administered DBG (150 mg 
od, 220 mg od) versus subcutaneous enoxaparin. METHODS: The RE-MOBILIZE 
study included 2596 knee-surgery patients and compared DBG to enoxaparin 30 mg 
bid. The RE-MODEL and RE-NOVATE studies included 2076 and 3463 patients 
undergoing knee and hip surgery respectively, and compared DBG with enoxaparin 
40 mg od. All studies used a randomised, double-blind, double-dummy non-inferiority 
design. Duration of treatment differed by study. Data collected for all patients included 
hospitalisation (main and re-admission), non-protocoled diagnostics, blood transfu-
sions, reoperations, concomitant medications and health care contacts for enoxaparin 
injections. Each resource use category was summarised, separately for each study, by 
and between treatment using means and standard errors. Two sample t-tests were used 
to examine differences between treatments. RESULTS: There were no consistently 
signiﬁcant differences between treatments (within each study). The percentages of 
patients requiring domiciliary nurse visits to administer thromboprophylaxis following 
discharge from hospital (i.e. administer subcutaneous enoxaparin or placebo because 
the patient was unable to self-inject) were 5.6% (DBG 150 mg od), 5.0% (DBG 
220 mg od) and 5.4% (enoxaparin) in RE-MOBILIZE, 1.0%, 1.5% and 1.9% in 
RE-MODEL, and 4.4%, 5.1% and 5.0% in RE-NOVATE. All domiciliary nurse visit 
comparisons for each DBG arm versus enoxaparin were statistically non-signiﬁcant 
(P > 0.15). CONCLUSIONS: Double-blind, double-dummy study designs appear to 
be unhelpful in the identiﬁcation of differences that might arise from changes in treat-
ment formulation and route of administration. In this study, a hypothesised difference 
in domiciliary nurse treatment administrations remained undetected due to the double-
dummy nature of the trials.
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OBJECTIVES: Efﬁcient facility operation is an important factor in quality of care for 
hospitals. How treatment protocols inﬂuences efﬁciency and productivity of a cardiac 
hospital is little known. METHODS: A discrete event simulation model of a cardiac 
hospital with percutaneous coronary intervention (PCI) capability was built on analy-
sis of time-stamped electronic medical record database (Cerner Health Facts®). Addi-
tional data were obtained from PCI literature, TRITON TIMI-38 trial, hospital 
statistics, and expert opinions. ACS treatment options include PCI, coronary arterial 
bypass graft (CABG), or drug therapy. Three oral antiplatelet dosing strategies for 
unstable angina (UA) and non-ST segment myocardial infarction (NSTEMI) were 
considered with loading dose given at PCI, minimum 2 hours prior, and minimum 6 
hours prior to PCI. Facility occupancy, wait, PCI volume, and length of stay, were 
tracked. RESULTS: Pre-treatment strategy increased patients’ total time in the hospital 
for all ACS-PCI, with an average time of 114.96 hours with loading dose at PCI, 
118.32 hours (+2.92%) with minimum 2 hours prior, and 121.68 hours (+5.85%) 
with minimum 6 hours prior. For UA/NSTEMI subgroup, total time in hospital was 
129.04 hours with loading at PCI, 134.51 hours (+4.24%) with minimum 2 hours 
prior, and 140.38 hours (+8.79%) with minimum 6 hours prior to PCI. Increase was 
mainly in pre-procedure time. Pre-treatment has no signiﬁcant effect on procedure 
times. Among the CABG-bound patients, pre-operation times increased by 33.49 
hours (+85.77%) and 35.47 hours (+90.83%) under 2 and 6 hour pre-treatment 
strategy, respectively. CONCLUSIONS: Pretreatment strategy with oral antiplatelet is 
likely to cause some inefﬁciency in hospital due to waits and longer total stay. This 
may increase facility congestion, occupancy, and staff hours. In CABG-bound patients, 
pretreatment leads to additional days due to recommended wait. The pretreatment 
strategy as a way to optimize antiplatelet therapy in ACS-PCI entails efﬁciency costs.
CARDIOVASCULAR DISORDERS – Patient-Reported Outcomes Studies
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CONCORDANCE AMONG THREE SELF-REPORTED MEASURES OF 
MEDICATION ADHERENCE AND COUNT OF TABLETS RECORDS IN 
COLOMBIAN HYPERTENSIVE PATIENTS
Garcia Vega OA, Buendia Rodriguez JA
Universidad Nacional de Colombia, Bogota, Colombia
OBJECTIVES: To evaluate the level of agreement among three previously validated 
self-reported medication adherence measures and count of tablets records METHODS: 
This was a cross-sectional study which included adult patients (40 and older) with 
hypertension disease enrolled continuously for 6 months in a private medical center. 
Random sequences of tests (communication of self-compliance (SC), Morinsky-Green 
Test (MG) and knowledge of the illness (KI)) were used to estimate the adherence of 
antihypertensive medication. Threshold of 80% was used to determine adherence with 
count of tablets. Concordances were assessed using Cohen’s kappa coefﬁcient (k) and 
prevalence-adjusted bias-adjusted kappa (PABAK). RESULTS: A total of 151 hyper-
tensive patients were included in the study. A total of 65.5% of these patients have 
other comorbilities and 45.6% took more than 5 drugs per day. The prevalence of 
non adherence, using a tablet count as reference test, was 8%. Due substantial imbal-
ance in the fourfold table’s marginal totals we found high agreement of negative results 
(SC (0, 94), MG (0.60), KI (0.72)) but low Kappa (SC (k:- 0,03), MG (k: 0,06), KI 
(k:−0,01)).The Kappa values adjusted (PABAK) were SC (k:0.79), MG (k: −0,06), KI 
(k:0,15). CONCLUSIONS: Because of the weak to moderate concordance found 
among validated measures of adherence, the selection of a useful adherence measure 
in clinical practice is difﬁcult. These ﬁndings underscore the difﬁculty in both assessing 
patients’ medication-taking behavior and assessing and comparing the results of adher-
ence research. The development of valid and reliable measures for easily assessing 
medication adherence behavior in clinical setting is needed.
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OBJECTIVES: To develop predictive models for medication compliance in dyslipid-
emia that will aid health care decision makers in targeting compliance intervention 
programs. METHODS: Pharmacy and medical claims data from a commercial health 
plan were analyzed for all currently enrolled members who received their ﬁrst dyslip-
idemic medication between May 1, 2007 and April 30, 2008. Percentage of days 
covered (PDC) deﬁned as days supply of dyslipidemic medication per 365 days. PDC 
< 80% was used to categorize non-compliant patients. Potential independent variables 
included patient demographics, pharmacy utilization and medical conditions. Stepwise 
logistic regression was used to predict the odds of non-compliance. RESULTS: A total 
of 88,635 patients were included. Sixty-ﬁve percent of patients were non-compliant 
(PDC = 0.33; SD = 0.22). The most signiﬁcant predictor of non-compliance was treat-
ment with bile acid sequestrants (OR: 6.75; p < 0.0001, compared to statins). Signiﬁ-
cant predictors of non-compliance also included age category, increasing from an OR 
= 1.11 for age 45–55 to OR = 3.23 for age <18 [p < 0.0001 for all estimates compared 
to age 75+]; prior diabetes diagnosis (OR: 1.15, p < 0.0001) and the number of unique 
pharmacies used (OR = 1.10 per additional pharmacy; p < 0.0001). Factors reducing 
non-compliance include male gender (OR: 0.77, p < 0.0001); previous heart attack 
(OR: 0.82; p = 0.0221); prior compliant behavior (OR: 0.888; p < 0.0001); number 
of unique physicians seen for medications (OR: 0.969 per additional physician; p < 
0.0001) and copayment categories (relative to no copayment). Compliance signiﬁ-
cantly improved by 12%, 12% and 6% for copay categories $5–$10, $10–$20, and 
$20–$30, respectively to no copayment. (p < 0.01). CONCLUSIONS: The results may 
